A phase Ib/II study of eribulin in combination with cyclophosphamide in patients with advanced breast cancer

[11] Funahashi Y(2014)Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models Cancer Sci 105 1334-1342

[12] Cortes J(2011)Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study The Lancet 377 914-923

[13] Twelves C(2014)Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies Breast Cancer Res Treat 148 553-561

[14] Cortes J(2015)Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial Breast Cancer Res Treat 154 509-520

[15] Pivot X(2016)Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy Ann Oncol 27 1525-1531

[16] Twelves C(2014)Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies Breast Cancer Res Treat 148 553-561

[17] Jones S(2009)Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735 J Clin Oncol 27 1177-1183

[18] Nitz U(2019)West German study PlanB trial: adjuvant four cycles of epirubicin and cyclophosphamide plus docetaxel versus six cycles of docetaxel and cyclophosphamide in HER2-negative early breast cancer J Clin Oncol 37 799-808

[19] Blum JL(2017)Anthracyclines in early breast cancer: the abc trials—usor 06–090, nsabp b-46-i/usor 07132, and nsabp b-49 (nrg oncology) J Clin Oncol 35 2647-84

[20] Twelves C(2016)Subgroup analyses from a phase 3, open-label, randomized study of eribulin mesylate versus capecitabine in pretreated patients with advanced or metastatic breast cancer Breast Cancer 10 77-44

[11] Funahashi Y(2014)Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models Cancer Sci 105 1334-1342

[12] Cortes J(2011)Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study The Lancet 377 914-923

[13] Twelves C(2014)Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies Breast Cancer Res Treat 148 553-561

[14] Cortes J(2015)Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial Breast Cancer Res Treat 154 509-520

[15] Pivot X(2016)Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy Ann Oncol 27 1525-1531

[16] Twelves C(2014)Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies Breast Cancer Res Treat 148 553-561

[17] Jones S(2009)Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735 J Clin Oncol 27 1177-1183

[18] Nitz U(2019)West German study PlanB trial: adjuvant four cycles of epirubicin and cyclophosphamide plus docetaxel versus six cycles of docetaxel and cyclophosphamide in HER2-negative early breast cancer J Clin Oncol 37 799-808

[19] Blum JL(2017)Anthracyclines in early breast cancer: the abc trials—usor 06–090, nsabp b-46-i/usor 07132, and nsabp b-49 (nrg oncology) J Clin Oncol 35 2647-84

[20] Twelves C(2016)Subgroup analyses from a phase 3, open-label, randomized study of eribulin mesylate versus capecitabine in pretreated patients with advanced or metastatic breast cancer Breast Cancer 10 77-44